Literature DB >> 17347325

Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.

A Pál1, D Méhn, E Molnár, S Gedey, P Mészáros, T Nagy, H Glavinas, T Janáky, O von Richter, G Báthori, L Szente, P Krajcsi.   

Abstract

ABCG2, a transporter of the ATP-binding cassette family, is known to play a prominent role in the absorption, distribution, metabolism, and excretion of xenobiotics. Drug-transporter interactions are commonly screened by high-throughput systems using transfected insect and/or human cell lines. The determination of ABCG2-ATPase activity is one method to identify ABCG2 substrate and inhibitors. We demonstrate that the ATPase activities of the human ABCG2 transfected Sf9 cell membranes (MXR-Sf9) and ABCG2-overexpressing human cell membranes (MXR-M) differ. Variation due to disparity in the glycosylation level of the protein had no effect on the transporter. The influence of cholesterol on ABCG2-ATPase activity was investigated because the lipid compositions of insect and human cells are largely different from each other. Differences in cholesterol content, shown by cholesterol loading and depletion experiments, conferred the difference in stimulation of basal ABCG2-ATPase of the two cell membranes. Basal ABCG2-ATPase activity could be stimulated by sulfasalazine, prazosin, and topotecan, known substrates of ABCG2 in cholesterol-loaded MXR-Sf9 and MXR-M cell membranes. In contrast, ABCG2-ATPase could not be stimulated in MXR-Sf9 or in cholesterol-depleted MXR-M membranes. Moreover, cholesterol loading significantly improved the drug transport into inside-out membrane vesicles prepared from MXR-Sf9 cells. MXR-M and cholesterol-loaded MXR-Sf9 cell membranes displayed similar ABCG2-ATPase activity and vesicular transport. Our study indicates an essential role of membrane cholesterol for the function of ABCG2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347325     DOI: 10.1124/jpet.106.119289

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  Recombinant synthesis of human ABCG2 expressed in the yeast Saccharomyces cerevisiae: an experimental methodological study.

Authors:  Anna Jacobs; Dana Emmert; Svenja Wieschrath; Christine A Hrycyna; Michael Wiese
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

2.  ATP-binding cassette transporter G2 activity in the bovine spermatozoa is modulated along the epididymal duct and at ejaculation.

Authors:  Julieta Caballero; Gilles Frenette; Olivier D'Amours; Maurice Dufour; Richard Oko; Robert Sullivan
Journal:  Biol Reprod       Date:  2012-06-14       Impact factor: 4.285

Review 3.  From cholesterogenesis to steroidogenesis: role of riboflavin and flavoenzymes in the biosynthesis of vitamin D.

Authors:  John T Pinto; Arthur J L Cooper
Journal:  Adv Nutr       Date:  2014-03-01       Impact factor: 8.701

Review 4.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

5.  Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.

Authors:  Ágnes Telbisz; Csilla Hegedüs; András Váradi; Balázs Sarkadi; Csilla Özvegy-Laczka
Journal:  Drug Metab Dispos       Date:  2014-01-02       Impact factor: 3.922

6.  Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.

Authors:  Suneet Shukla; Candice Schwartz; Khyati Kapoor; Abdul Kouanda; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2011-10-31       Impact factor: 3.922

Review 7.  ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

Authors:  Saroj Velamakanni; Shen L Wei; Tavan Janvilisri; Hendrik W van Veen
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

8.  ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.

Authors:  Tomoka Gose; Talha Shafi; Yu Fukuda; Sourav Das; Yao Wang; Alice Allcock; Ailsa Gavan McHarg; John Lynch; Taosheng Chen; Ikumi Tamai; Anang Shelat; Robert C Ford; John D Schuetz
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

9.  Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.

Authors:  Guillermo Moreno-Sanz; Borja Barrera; Andrea Armirotti; Sine M Bertozzi; Rita Scarpelli; Tiziano Bandiera; Julio G Prieto; Andrea Duranti; Giorgio Tarzia; Gracia Merino; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2014-06-30       Impact factor: 7.658

Review 10.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.